Document is current

Article History

Received: 27 March 2024

Revised: 9 September 2024

Accepted: 25 September 2024

First Online: 17 October 2024

Competing interests

: All members of the ERN GENTURIS CMMRD Guideline Group, including the Core Working Group, have provided disclosure statements on all relationships that they have that might be perceived to be a potential conflict of interest. Amedeo Azizi reports receipt of honoraria or consultation fees from Alexion, AstraZeneca and Novartis. Kevin Beccaria reports previous employment with Carthera SAS. Laurence Brugières reports receipts of honoraria or consultation fees from ESAI and TAKEDA. Chrystelle Colas reports receipt of honoraria or consultation fees from AstraZeneca. Volodia Dangouloff-Ros reports receipt of grants/research support from GE Healthcare. Richard Gallon reports receipt of grants/research support from Cancer Research UK Catalyst and UK National Health Service. Christian Kratz reports support from BMBF ADDRess (01GM1909A) and Deutsche Kinderkrebsstiftung (DKS2021.25). Magali Svrcek reports receipt of grants/research support from Bayer and Roche, and receipt of honoraria or consultation fees from Astellas, MSD and Sanofi. All participants of the ERN GENTURIS CMMRD Delphi survey have provided disclosure statements on all relationships that they have that might be perceived to be a potential source of a competing interests. Andishe Attarbaschi reports receipt of honoraria or consultation fees from Amgen, Novartis, Jazz, Gilead and MSD. Patrick Benusiglio reports receipt of honoraria or consultation fees from AstraZeneca, BMS and MSD. Christof Kramm reports receipt of grants/research support from Deutsche Kinderkrebsstiftung (non-commercial), research collaboration with Bayer to develop NTRK-inhibitors, being a member of the advisory board for Boehringer Ingelheim, and participation in Blueprint Medicines ROVER trial NCT04773782. Eric Legius reports receipt of honoraria or consultation fees from Alexion and AstraZeneca. Rianne Oostenbrink reports receipt of grants/research support from EU Patient-centric clinical trial platform (EU-PEARL), which includes support from the European Union’s Horizon 2020 research and innovation program, EFPIA, Children’s Tumor Foundation, Global Alliance for TB Drug Development non-profit organization and Springworks Therapeutics Inc., receipt of honoraria or consultation fees from AstraZeneca, and participation in a speaker’s bureau sponsored by Alexion. Enrico Opocher reports receipt of honoraria or consultation fees from Alexion (RareDisease). Markus G. Seidel reports receipt of grants/research support from Takeda, Amgen and Novartis, and receipt of honoraria or consultation fees from Jazz, Amgen and Novartis.